Immunovant, Inc. IMVT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s total current liabilities?
- Immunovant, Inc. (IMVT) reported total current liabilities of $104.42M in Q1 2026.
- How has Immunovant, Inc.'s total current liabilities changed year-over-year?
- Immunovant, Inc.'s total current liabilities increased by 51.8% year-over-year, from $68.78M to $104.42M.
- What is the long-term trend for Immunovant, Inc.'s total current liabilities?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s total current liabilities has grown at a 40.9% compound annual growth rate (CAGR), from $18.77M to $104.42M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.